Vivimed Labs PE ratio history and valuation
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.75down ₹0.11 (1.88%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹5.86.
28 Oct: open ₹5.75, high ₹5.75, low ₹5.75
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 348
Vivimed Labs' dividend yield on 28 Oct 2026, each against its own history of up to 10 years. It has no P/E yet: twelve months of its results are not on record.
Vivimed Labs PE ratio and valuation against its own history
- Price to earningsNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to bookNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.No results for a period ending in the last six months, or nine for a company filing half-yearly
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.No results for a period ending in the last six months, or nine for a company filing half-yearly
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 197 days
10 years
Median 0.00%Today is at or above 72% of the 1,767 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.No results for a period ending in the last six months, or nine for a company filing half-yearly
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.8,29,13,915at 31 Mar 2026
₹ crore.Vivimed Labs financials ›
Vivimed Labs valuation at each year end
On the last trading day of each March, the month the company's year ends.Vivimed Labs dividend history
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 871 | 587 | 192 | 60 | 133 | 120 | 55 | 44 |
| Price to earnings | 7.3 | 3.2 | 2.9 | Loss | Loss | Loss | Loss | Loss |
| Price to book | No balance sheet | No balance sheet | 0.2 | 0.1 | 0.2 | 0.3 | 0.2 | Negative net worth |
| Price to sales | 0.6 | 0.4 | 0.2 | 0.1 | 0.1 | 0.6 | 0.3 | 0.5 |
| EV to EBITDA | No balance sheet | No balance sheet | 5.0 | 14.8 | 47.8 | Operating loss | Operating loss | Operating loss |
| Dividend yield | 0.00% | 0.56% | 1.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | 13.7% | 30.9% | 34.7% | −80.3% | −82.3% | −63.9% | −147.8% | −78.8% |
A ratio that does not exist on the day says why in its cell.
Vivimed Labs market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Dividends and the public's market cap
From the close on 28 Oct 2026.
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹44 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Vivimed Labs is 176th among them by market cap. Each median leaves out Vivimed Labs itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.1Across 158 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 191 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.5Across 147 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.49%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Onyx BiotecONYX | 65 | – | 1.18 | – | 0.00% |
 Rekvina LaboratoriesVINRKLB | 64 | – | – | – | 0.00% |
 Zenith DrugsZENITHDRUG | 63 | 16.09 | 0.87 | – | 0.00% |
 PhaarmasiaPHRMASI | 57 | 3.21 | 2.56 | 25.5 | 0.00% |
| Vivimed LabsVIVIMEDLAB | 48 | – | – | – | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 48 | 98.36 | 2.21 | 60.3 | 0.00% |
 Mangalam Drugs and OrganicsMANGALAM | 46 | – | 0.45 | – | 0.00% |
 ANG Lifesciences IndiaANG | 44 | – | 0.83 | – | 0.00% |
 Vasundhara RasayansVRL | 44 | 7.37 | 1.07 | 7.0 | 1.46% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.